Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Debra Resta"'
Autor:
Franck E. Nicolini, Gert J. Ossenkoppele, Philipp le Coutre, Ariful Haque, Kapil N. Bhalla, Mark R. Litzow, Francesca Palandri, Yaping Shou, Stephen G. O'Brien, Giuliana Alimena, Hagop M. Kantarjian, Norbert Gattermann, Aaron Weitzman, Francis J. Giles, Francisco Cervantes, Andreas Hochhaus, Ravi Bhatia, Debra Resta
Publikováno v:
Blood. 110:3540-3546
Nilotinib, an orally bioavailable, selective Bcr-Abl tyrosine kinase inhibitor, is 30-fold more potent than imatinib in pre-clinical models, and overcomes most imatinib resistant BCR-ABL mutations. In this phase 2 open-label study, 400 mg nilotinib w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7a3823c4d225e024dc0c24326ba9e60
https://doi.org/10.1182/blood-2007-03-080689
https://doi.org/10.1182/blood-2007-03-080689
Autor:
Mary Beth Riley, John L. Frater, Martin S. Tallman, Mary Ann Hrisinko, Debra Resta, Brian J. Druker, Daina Variakojis, LoAnn Peterson
Publikováno v:
American Journal of Clinical Pathology. 119:833-841
We evaluated bone marrow pathologic features and cytogenetic and molecular genetic status of 13 patients with interferon-resistant, chronic-phase chronic myeloid leukemia (CML), treated with imatinib mesylate (Gleevec). All had morphologic evidence o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6af6135fe8942ef3bf68dcafc1d8077d
https://doi.org/10.1309/a4rgp4lf12ggh8mw
https://doi.org/10.1309/a4rgp4lf12ggh8mw
Autor:
R N Debra Resta, Thomas B. Sneed, R N Mary Beth Rios, Jorge E. Cortes, Moshe Talpaz, Stefan Faderl, B. Nebiyou Bekele, Xian Zhou, Susan O'Brien, Francis Giles, William G. Wierda, Hagop Kantarjian
Publikováno v:
Cancer. 100:116-121
BACKGROUND Imatinib mesylate induces high rates of hematologic and cytogenetic response in patients with chronic myelogenous leukemia (CML). During therapy with imatinib, up to 45% of patients with CML reportedly experience myelosuppression ≥ Grade
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d68d0944c57626b2de225cc634d380b
https://doi.org/10.1002/cncr.11863
https://doi.org/10.1002/cncr.11863
Autor:
Charles L. Sawyers, Sayuri Ohno-Jones, Hagop M. Kantarjian, Elisabeth Buchdunger, John Ford, Bin Peng, Brian J. Druker, Debra Resta, Nicholas B. Lydon, Renaud Capdeville, Moshe Talpaz
Publikováno v:
New England Journal of Medicine. 344:1031-1037
BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML). Since tyrosine kinase activity is essential to the transforming function of BCR-ABL, an inhibitor of the kinase could be an effective treatment for CML.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ba11053194554b64afd7a42cee23988
https://doi.org/10.1056/nejm200104053441401
https://doi.org/10.1056/nejm200104053441401
Autor:
Moshe Talpaz, Renaud Capdeville, Peter Lloyd, Charles L. Sawyers, Amy Racine-Poon, Michael Hayes, Debra Resta, Brian J. Druker, Bin Peng, Marianne Rosamilia, John Ford
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 22(5)
Purpose To evaluate the basic pharmacokinetic (PK) characteristics of imatinib mesylate and assess the relationship between the PK and pharmacodynamic (PD) properties of the drug. Patients and Methods The PK and PD properties of imatinib were investi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::307e986417533a5b4b273add6dc9902f
https://pubmed.ncbi.nlm.nih.gov/15923584
https://pubmed.ncbi.nlm.nih.gov/15923584
Autor:
John L, Frater, Martin S, Tallman, Daina, Variakojis, Brian J, Druker, Debra, Resta, Mary Beth, Riley, Mary Ann, Hrisinko, LoAnn C, Peterson
Publikováno v:
American journal of clinical pathology. 119(6)
We evaluated bone marrow pathologic features and cytogenetic and molecular genetic status of 13 patients with interferon-resistant, chronic-phase chronic myeloid leukemia (CML), treated with imatinib mesylate (Gleevec). All had morphologic evidence o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9a29e4453646421fe7a5e6eebc9db240
https://pubmed.ncbi.nlm.nih.gov/12817431
https://pubmed.ncbi.nlm.nih.gov/12817431
Autor:
Hagop M, Kantarjian, Susan, O'Brien, Jorge E, Cortes, Terry L, Smith, Mary Beth, Rios, Jianqin, Shan, Ying, Yang, Francis J, Giles, Deborah A, Thomas, Stefan, Faderl, Guillermo, Garcia-Manero, Sima, Jeha, William, Wierda, Jean-Pierre J, Issa, Steven M, Kornblau, Michael, Keating, Debra, Resta, Renaud, Capdeville, Moshe, Talpaz
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 8(7)
Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown encouraging activity in chronic myelogenous leukemia (CML).We treated 237 patients (median age, 50 years; age range, 18-82 years) with Philadelphia chromosome (Ph)-positive ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7ab3a275a36510b046b382309a4296bf
https://pubmed.ncbi.nlm.nih.gov/12114417
https://pubmed.ncbi.nlm.nih.gov/12114417
Autor:
M. Talpaz, Stefan Faderl, D. A. Thomas, Debra Resta, M. Albitar, Francis Giles, Guillermo Garcia-Manero, Jianqin Shan, Hagop M. Kantarjian, Jorge E. Cortes, Mary Beth Rios, Susan O'Brien
Publikováno v:
Blood. 99(10)
Molecular abnormalities caused by the hybrid Bcr-Abl gene are causally associated with the development and progression of Philadelphia chromosome–positive (Ph+) chronic myelogenous leukemia (CML). Imatinib mesylate (STI571), a specific Bcr-Abl tyro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dfba0a8300ebef42cfb550d3d0c159d
https://pubmed.ncbi.nlm.nih.gov/11986206
https://pubmed.ncbi.nlm.nih.gov/11986206
Autor:
Hagop, Kantarjian, Charles, Sawyers, Andreas, Hochhaus, Francois, Guilhot, Charles, Schiffer, Carlo, Gambacorti-Passerini, Dietger, Niederwieser, Debra, Resta, Renaud, Capdeville, Ulrike, Zoellner, Moshe, Talpaz, Brian, Druker, John, Goldman, Stephen G, O'Brien, Nigel, Russell, Thomas, Fischer, Oliver, Ottmann, Pascale, Cony-Makhoul, Thierry, Facon, Richard, Stone, Carole, Miller, Martin, Tallman, Randy, Brown, Michael, Schuster, Thomas, Loughran, Alois, Gratwohl, Franco, Mandelli, Giuseppe, Saglio, Mario, Lazzarino, Domenico, Russo, Michele, Baccarani, Enrica, Morra
Publikováno v:
The New England journal of medicine. 346(9)
Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase.A total of 532 patients with late--chronic-phase CML
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::352c4b1459afa210623f00172de193a2
https://pubmed.ncbi.nlm.nih.gov/12167692
https://pubmed.ncbi.nlm.nih.gov/12167692
Autor:
David T. Scadden, Debra Resta, Zhengyu Wang, Scott M. Hammer, Jocelyn Bresnahan, John Gere, James D. Levine, Jacqueline McGRATH, Diane Young
Publikováno v:
AIDS research and human retroviruses. 11(6)
To determine the safety, tolerance, and hematological and virological effects of the recombinant hematopoietic growth factor interleukin 3 (IL-3) in HIV-1-infected individuals with cytopenia.A phase I single-center trial was conducted with patients i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2ff0a17a373d7ca361d2c6da56b0108
https://pubmed.ncbi.nlm.nih.gov/7576933
https://pubmed.ncbi.nlm.nih.gov/7576933